近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
1. Sun Y, Yu XL, Luo W, Lee AWM, Wee JTS, Lee N, Zhou GQ, Tang LL, Tao CJ, Guo R, Mao YP, Zhang R, Guo Y, Ma J. Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. Radiother Oncol. 2014 Mar;110(3):390-7. (IF 4.4)2. Sun Y, Zhou GQ, Qi ZY, Zhang L, Huang SM, Liu LZ, Li L, Lin AH, Ma J. Radiation-induced temporal lobe injury after intensity modulated radiotherapy in nasopharyngeal carcinoma patients: a dose-volume-outcome analysis. BMC Cancer. 2013;13:397 (IF 3.4)3. Sun Y, Tang LL, Chen L, Li WF, Mao YP, Liu LZ, Lin AH, Li L, Ma J. Promising treatment outcomes of intensity-modulated radiation therapy for nasopharyngeal carcinoma patients with N0 disease according to the seventhedition of the AJCC staging system. BMC Cancer, 2012;12:68 (IF:3.4)4. Sun Y, Guo R, Yin WJ, Tang LL, Yu XL, Chen M, Qi ZY, Liu MZ, Ma J. Which T category of nasopharyngeal carcinoma may benefit most from volumetric modulated arc therapy compared with step and shoot intensity modulated radiation therapy. Plos One. 2013;8(9):e75304 (IF 3.2)5. Ji-Jin Yao,Guan-Qun Zhou, Xiao-Li Yu, Ling-Long Tang, Lei Chen, Yan-Ping Mao, Li Lin, Lu-Lu Zhang, Jian-Yong Shao, Ying Guo, Jun Ma, and Ying Sun(Correspondence author).Incidence of and Risk Factors for Mastoiditis after Intensity Modulated Radiotherapy in Nasopharyngeal Carcinoma. PLos One,2015. ( IF 3.2)6. Tao CJ, Lin L, Zhou GQ, Tang LL, Chen L, Mao YP, Zeng MS, Kang TB, Jia WH, Shao JY, Mai HQ, Lin AH, Ma J, Sun Y (Correspondence author). The long-term survival and toxicity comparison of weekly cisplatin versus three-weekly cisplatin delivered concurrently with intensity modulated radiotherapy in nasopharyngeal carcinoma. Plos One, 2014; 9(10): e110765. (IF 3.2)7. Sun Y, Yu XL, Zhang GS, Liu YM, Tao CJ, Guo R, Tang LL, Zhang R, Guo Y, Ma J . Reduction of the clinical target volume in patients with lateralized cancer of the nasopharynx and without contralateral lymph node metastasis receiving intensity modulated radiotherapy. Head Neck. 2015 Feb 9. (IF 3.0)8. Mao YP, Yin WJ, Guo R, Zhang GS, Fang JL, Chi F, Qi ZY, Liu MZ, Ma J, Sun Y (Correspondence author). Dosimetric benefit to organs at risk following margin reductions in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. Chin J Cancer, 2015. (IF 2.2)9. Tao CJ, Liu X, Tang LL, MaoYP, Chen L, Li WF, Yu XL, Liu LZ, Zhang R, Lin AH, Ma J, Sun Y (Correspondence author).Chin J C Prognostic scoring system for locoregional control among nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Chin J Cancer, 2013; 32(9): 494-501 (IF 2.2)10. Tao CJ, Liu X, Tang LL, MaoYP, Chen L, Li WF, Yu XL, Liu LZ, Zhang R, Lin AH, Ma J, Sun Y (Correspondence author). Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma. Chin J Cancer, 2013; 32(10):525-532(IF 2.2)11. Liu N, Cui RX, Sun Y (Co-first authors), Guo R, Mao YP, Tang LL, Jiang W, Liu X, Cheng YK, He QM, Cho WC, Liu LZ, Li L, Ma J. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma. Int J Cancer, 2014; 134: 1359-1368. (IF 5.1)12. Chen Y, Sun Y (Co-first authors), Liang SB, Zong JF, Li WF, Chen M, Chen L, Mao YP, Tang LL, Guo Y, Lin AH, Liu MZ, Ma J. Progress Report of a Randomized Trial Comparing Long-term Survival and Late Toxicity of Concurrent Chemoradiotherapy with Adjuvant Chemotherapy to Radiotherapy Alone in Stage III–IVB Nasopharyngeal Carcinoma Patients from Endemic Regions of China. Cancer, 2013; 119(12):2230-8 (IF 4.9)13. Tang LL, Sun Y(Co-first authors), Mao YP, Chen Y, Li WF, Chen L, Liu LZ, Lin AH, Li L, Ma J. Prognostic value of parapharyngeal extension in nasopharyngeal carcinoma treated with intensity modulated radiotherapy. Radiother Oncol. 2013 (IF 4.4)14. Guo R, Sun Y (Co-first authors), Yu XL, Tang LL, Yin WJ, Qi ZY, Ma J. Is primary tumor volume still a prognostic factor in Intensity modulated radiation therapy for nasopharyngeal carcinoma? Radiother Oncol, 2012; 104(3):294-299 (IF 4.4)15. Li WF, Sun Y (Co-first authors), Mao YP, Chen L, Chen YY, Chen M, Liu LZ, Lin AH, Li L, Ma J. A proposed N staging system using the International Consensus Guidelines for lymph node levels is predictive for nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy in endemic areas. Int J Radiat Oncol Biol Phys, 2013;86(2):249-56 (IF:4.3)16. Liang SB, Sun Y (Co-first authors), Liu LZ, Mao YP, Tang LL, Chen Y, Tian L, Lin AH, Liu MZ, Li L, Ma J. Extension of Local Disease in Nasopharyngeal Carcinoma as Detected by magnetic resonance imaging: improvement of clinical target volume delineation. Int J Radiat Oncol Biol Phys, 2009;75(3):742-750 (IF:4.3)17. Yin WJ, Sun Y (Co-first authors), Chi F, Fang JL, Guo R, Yu XL, Mao YP, Qi ZY, Guo Y, Liu MZ, Ma J. Evaluation of inter-fraction and intra-fraction errors during volumetric modulated arc therapy in nasopharyngeal carcinoma patients. Radiat Oncol, 2013;8:78 (IF 2.5)
京公网安备 11010802027423号